MXPA04004290A - Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido. - Google Patents

Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido.

Info

Publication number
MXPA04004290A
MXPA04004290A MXPA04004290A MXPA04004290A MXPA04004290A MX PA04004290 A MXPA04004290 A MX PA04004290A MX PA04004290 A MXPA04004290 A MX PA04004290A MX PA04004290 A MXPA04004290 A MX PA04004290A MX PA04004290 A MXPA04004290 A MX PA04004290A
Authority
MX
Mexico
Prior art keywords
fluid bed
compositions prepared
granulation process
bed granulation
intraorally disintegrating
Prior art date
Application number
MXPA04004290A
Other languages
English (en)
Spanish (es)
Inventor
Takahashi Koji
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA04004290A publication Critical patent/MXPA04004290A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
MXPA04004290A 2001-11-07 2002-11-07 Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido. MXPA04004290A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35017901P 2001-11-07 2001-11-07
PCT/US2002/035664 WO2003039472A2 (en) 2001-11-07 2002-11-07 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process

Publications (1)

Publication Number Publication Date
MXPA04004290A true MXPA04004290A (es) 2004-08-11

Family

ID=23375540

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004290A MXPA04004290A (es) 2001-11-07 2002-11-07 Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido.

Country Status (7)

Country Link
EP (1) EP1446088A2 (https=)
JP (1) JP2005512990A (https=)
AU (1) AU2002361596A1 (https=)
BR (1) BR0213973A (https=)
CA (1) CA2466030A1 (https=)
MX (1) MXPA04004290A (https=)
WO (1) WO2003039472A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2026770A1 (en) * 2006-06-12 2009-02-25 Schering Corporation Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders
CN101762646B (zh) * 2008-12-26 2012-09-05 扬子江药业集团有限公司 一种测定拉克替醇含量的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122141B2 (ja) * 1994-01-31 2001-01-09 山之内製薬株式会社 口腔内溶解型圧縮成型物及びその製造法
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
JPH0867623A (ja) * 1994-08-31 1996-03-12 Taisho Pharmaceut Co Ltd 矯味経口製剤用組成物
DE19617487A1 (de) * 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
JP2003516353A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション ヴァルデコキシブ組成物
ATE283048T1 (de) * 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物

Also Published As

Publication number Publication date
CA2466030A1 (en) 2003-05-15
EP1446088A2 (en) 2004-08-18
JP2005512990A (ja) 2005-05-12
BR0213973A (pt) 2004-08-31
WO2003039472A3 (en) 2003-09-25
WO2003039472A2 (en) 2003-05-15
AU2002361596A1 (en) 2003-05-19

Similar Documents

Publication Publication Date Title
AP2004002998A0 (en) Intraorally disintegrating valdecoxib compositions
MXPA02006151A (es) Composiciones de liberacion dual de un inhibidor de ciclooxigenasa-2.
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
UA58576C2 (uk) Фармацевтична композиція, що містить целекоксиб
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
MXPA05013075A (es) Inhibidores de p-38 basados en heterociclo de 5 miembros.
WO2003057144A3 (en) Change inhibitors of dipeptidyl peptidase iv
TW200510416A (en) P38 inhibitors and methods of use thereof
IL164187A0 (en) 7-Azaindole derivatives and pharmaceutical compositions containing the same
AP1408A (en) Phenyl yanthine derivatives.
GEP20053510B (en) Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors
NO976048D0 (no) Farmasöytiske og diett formuleringer for profylakse og behandling av mave- og tarmforstyrrelser
TW200621765A (en) Substituted phenylaminothiazoles and their use
TNSN08279A1 (en) Bayer healthcare ag
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
MXPA04004290A (es) Composiciones de valdecoxib que se disgregan intraoralmente preparadas mediante un procedimiento de granulacion en lecho fluido.
IS2849B (is) Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting
YU37104A (sh) Preparati valdekoksiba sa oralnim razlaganjem dobijeni postupkom sušenja raspršivanjem
WO2003029221A8 (de) Tetrahydroisochinoline, ihre herstellung und verwendung als schmerzmittel
TNSN05307A1 (en) 5-membered heterocycle-based p38 kinase inhibitors
WO2004071383A3 (en) New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action